SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCity Lon Inv Regulatory News (CLIG)

Share Price Information for City Lon Inv (CLIG)

Share Price is delayed by 15 minutes
Get Live Data
443.00    10.00 (2.31%)
Bid:
440.00
Ask:
443.00
Spread: 3.00 (0.682%)
Market Cap: £218.72m
CLIG Live PriceLast checked at - London Stock Exchange

Intraday City Lon Inv Share Chart

Trading Update

17 Jun 2013 07:58

RNS Number : 1560H
City of London Investment Group PLC
17 June 2013
 



City of London Investment Group PLC

17 June 2013

CITY OF LONDON INVESTMENT GROUP PLC

("City of London" or "the Group")

TRADING UPDATE

for the Year to 31 May 2013

City of London (LSE: CLIG), a leading emerging markets asset management group, provides a trading update for its financial year ended 31 May 2013. The numbers that follow are all unaudited.

Funds under management were US$3.7 billion (£2.4 billion) at 31 May 2013 (2012: US$4.5 billion or £2.9 billion), representing a 17% decrease in US$ terms and a 16% decrease in sterling terms. Over the same period (31 May 2012 to 31 May 2013) the MSCI Emerging Markets Index (MXEF) increased by 11% in US$ terms.

For the year to 31 May 2013, City of London expects that pre-tax profits will be approximately £8.9 million (2012: £11.5 million), and that profits after an anticipated tax charge of £2.6 million (29% of pre-tax profits) will be approximately £6.3 million (2012: profits of £8.5 million after a tax charge of £3.0 million, representing 26% of pre-tax profit). Basic and fully diluted earnings per share are expected to be 24.9p and 24.6p respectively (2012: 33.8p and 32.8p). The above pre-tax figures are stated net of a compromise settlement of £700,000 agreed with two former executives.

The Group has established a dividend policy of 1.5 times earnings cover which is applied with flexibility. As a result of both falls in Emerging Markets, and client redemptions during the first half of the financial year, earnings cover will be reduced this year but given the Group's strong cash position and optimism with regard to the future, the Board is recommending a final dividend of 16p per share (2012: 16p). This would bring the total for the year to 24p (2012: 24p), making cover 1.04 times earnings per share (2012: 1.41 times).

As reported in our half year results, released 21 January 2013, we continue to focus on reducing costs and this has been achieved, resulting in an annualised saving of £1 million.

Investment performance of the Emerging Markets Closed End Fund Strategy has improved very significantly. As noted in last year's Trading Update, the momentum of corporate activity, coupled with mean reversion of net asset value performance and increasing discount volatility have been the major drivers of improved investment performance. With the size weighted average discount of emerging market closed end funds still quite wide, there continue to be trading opportunities to generate further outperformance. We are maintaining a robust pipeline of client additions.

Diversification efforts continue to focus on the Developed closed end fund strategy and the Frontier Emerging Markets Strategy, where both products continue to attract attention from consultants and institutional prospects.

The China A Share Strategy received a mandate for $25 million in December 2012 which closed the Qualified Foreign Institutional Investor account quota of $100 million approved for City of London Investment Management Company Limited (CLIM). A new application for an additional $100 million in QFII quota was requested from the China Securities Regulatory Commission in April 2013 and, if approved, will allow for new marketing opportunities.

City of London Investment Group expects to announce final full year results for the year to 31 May 2013 on 9 September 2013, followed by an Investor Day on 10 September. The Company's Annual General Meeting date and final dividend payment dates are expected to be 7 October 2013 and 25 October 2013 respectively.

Summary and unaudited trading update

Year to 31 May

2013

2012

Funds under Management (at period end)

US$3.7bn

US$4.5bn

Turnover (plus investment income)

£29.9m

£34.6m

Administrative expenses, commission payable, and profit-share

£21.0m

£23.1m

Profit before tax

£8.9m

£11.5m

Profit after tax

£6.3m

£8.5m

Profit per share, basic

24.9p

33.8p

Profit per share, diluted

24.6p

32.8p

 

Financials - consolidated income statement

Year to 31 May

£'000

2013

2012

Fee income

29,363

34,142

Interest & other

501

428

Finder's commission

(4,194)

(5,195)

Custody & Administration

(1,244)

(1,433)

Total net income

24,426

27,942

Costs:

Human resources

7,629

6,765

Premises

612

628

Communications & IT

1,534

1,619

Business development

695

909

General

1,041

1,135

Total costs

11,511

11,056

Operating profit

12,915

16,886

Profit-share

4,055

5,424

Pre-tax profit

8,860

11,462

Tax

(2,594)

(2,964)

Post-tax profit

6,266

8,498

Dividends (prior year final plus current year interim)

(6,046)

(6,052)

Retained

220

2,446

 

 

 

For further information, please visit www.citlon.co.uk or contact:

 

Barry Olliff (Chief Executive)

City of London Investment Group PLC

Tel: +44 (0)20 7711 0771 

 

Martin R Green

Canaccord Genuity Limited

Financial Adviser & Broker

Tel: +44 (0)20 7523 8000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSFDSMWFDSEIM
Date   Source Headline
20th Apr 20267:00 amRNSTrading Update for the quarter to 31 March 2026
7th Apr 20262:44 pmRNSPDMR Shareholding
31st Mar 20261:56 pmRNSEBT Share Purchase
26th Mar 202612:09 pmRNSEBT Share Purchase
25th Mar 202611:33 amRNSPDMR Shareholding
24th Mar 20269:56 amRNSEBT Share Purchase
13th Mar 20263:05 pmRNSPDMR Shareholding
10th Mar 20264:07 pmRNSEBT Share Purchase
10th Mar 20264:07 pmRNSEBT Share Purchase
9th Mar 202612:35 pmRNSPDMR Shareholding
4th Mar 202612:48 pmRNSGrant of LTIP Award
24th Feb 20267:00 amRNSHalf Year Results and Dividend Declaration
13th Feb 202611:00 amRNSInvestor Presentation
21st Jan 20267:00 amRNSAppointment of Chief Executive Officer
19th Jan 20267:00 amRNSTrading Update - Six months to 31 December 2025
29th Oct 20253:15 pmRNSPDMR/PCA Shareholding
29th Oct 20253:15 pmRNSPDMR Shareholding
29th Oct 20253:15 pmRNSPDMR Shareholding
29th Oct 20253:15 pmRNSPDMR Shareholding
27th Oct 20255:25 pmRNSResult of AGM
21st Oct 20255:00 pmRNSPDMR Shareholding
20th Oct 20257:00 amRNSTrading Update - Quarter to 30 September 2025
22nd Sep 20255:20 pmRNSCorrection: Final Results for year to 30 June 25
16th Sep 20257:00 amRNSFinal Results for the year to 30th June 2025
11th Sep 20257:00 amRNSInvestor Presentation via Investor Meet Company
5th Aug 20258:14 amRNSDirector Declaration
24th Jul 20257:00 amRNSPre-Close Trading Update
2nd Jul 20256:12 pmRNSBoard and Committee changes
1st Jul 202512:10 pmRNSDirector/PDMR Shareholding
17th Jun 20255:34 pmRNSDirector/PDMR Shareholding
13th Jun 20259:57 amRNSDirector/PDMR Shareholding
13th Jun 20259:47 amRNSHolding(s) in Company
10th Jun 20257:00 amRNSDirectorate Change
22nd Apr 20257:00 amRNSFUNDS UNDER MANAGEMENT 31 MARCH 25, TRADING UPDATE
7th Apr 20257:00 amRNSAPPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
25th Feb 20257:00 amRNSHalf Year Results
20th Jan 20257:00 amRNSSIX MONTHS TO 31 DECEMBER 2024 TRADING UPDATE
29th Oct 20245:27 pmRNSPDMR Dealing
29th Oct 20245:27 pmRNSPDMR Dealing
29th Oct 20245:26 pmRNSPDMR Dealing
28th Oct 20245:57 pmRNSResult of AGM & Board change - Replacement
28th Oct 20244:14 pmRNSResult of AGM and Board and Committee change
21st Oct 20247:00 amRNSTRADING UPDATE - Quarter to 30 September 2024
17th Oct 20244:46 pmRNSHolding(s) in Company
16th Oct 20241:02 pmRNSHolding(s) in Company
11th Oct 20244:50 pmRNSHolding(s) in Company
24th Sep 20247:00 amRNSFINAL RESULTS FOR THE YEAR TO 30TH JUNE 2024
13th Sep 20242:54 pmRNSFull Year Results release date
25th Jul 20247:00 amRNSPRE-CLOSE TRADING UPDATE
23rd May 20244:32 pmRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.